Optimum Strategic Communications’ Post

Simple Summary: Heat shock factor 1 (HSF1) is a transcription factor crucial for cellular stress responses. HSF1 activates heat shock proteins (HSPs) in response to proteotoxic stress, aiding in protein folding and maintaining proteostasis. HSF1 is often overexpressed in various cancer cells, fueling malignancy and indicating a poor prognosis. The mechanisms behind HSF1-induced tumorigenesis are complex and cancer type-dependent. Targeting HSF1 presents a novel cancer treatment strategy.

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer 📰 #CancerNews 📣 #MedicalOncology #ClinOnc ⚫️ #CancerTreatment #CancerResearch 🔖 #MedLearn

Exiting paper on the possibilities with repurposing already approved drugs for cancer therapy!

What is the current landscape of bispecific antibodies in lung cancer? What potential clinical targets exist? Our review in @Pharmaceut_MDPI with Atulya Aman Khosla, @ADesaiMD, @jatwanikaran, and @RohitBanwar explores these questions! Free to read: https://lnkd.in/gdrpgUZZ 🥳🥳🥳

Over the coming weeks, we preview reports sourced from around the world to assess the biggest potential new drugs of the year ahead. Typically, major #pharmaceutical and #biotechnology companies are featured, each presenting potential blockbuster launches. New Weapon in the Fight Against Lung Cancer: Datopotamab Deruxtecan Used for: Lung and breast cancers. AstraZeneca and Daiichi Sankyo US are betting big on datopotamab deruxtecan (Dato-DXd), their experimental cancer treatment that works as an antibody-drug conjugate (ADC), a hot area in oncology research right now. Lung cancer remains a significant health challenge, but there's promising news! A new drug called Datopotamab Deruxtecan (Dato-DXd) has shown encouraging results in clinical trials for patients with advanced non-squamous non-small cell lung cancer (NSCLC) who haven't responded well to previous treatments. How Does Dato-DXd Work? Dato-DXd is a type of drug called an antibody-drug conjugate (ADC). It combines two powerful components: Antibody: This targets a specific protein, TROP-2, which is often found on the surface of lung cancer cells. Chemotherapy drug: Once attached to the cancer cell, the ADC releases the chemotherapy drug, directly attacking the tumor. Early Signs of Promise Studies have shown Dato-DXd to be effective in extending progression-free survival (PFS) compared to standard chemotherapy in patients with previously treated NSCLC. This means patients experience a longer period without their cancer worsening. Important to Note: Dato-DXd is still under investigation and not yet widely available. More research is needed to understand its long-term effects and potential side effects. Looking Forward Dato-DXd represents a potential breakthrough in lung cancer treatment. As research continues, it may offer new hope for patients battling this challenging disease. Stay Informed: For more information on Datopotamab Deruxtecan and lung cancer research, you can visit: American Cancer Society #LungCancer #DatopotamabDeruxtecan #ClinicalTrials #CancerResearch Please note: This is a simplified explanation for educational purposes. It's recommended to consult with a healthcare professional for all specific medical advice.

As an advanced cancer patient looking at your treatment options, how can you decide what will work for you? If you have multiple drug options, how do you decide which ones have the best potential to make an impact for you and your unique cancer? The standard process for personalized cancer treatment is to sequence the DNA of your tumor, then identify mutations that point to a particular drug. But even with more and more highly-targeted drugs being developed, the odds of finding an “actionable” mutation are still low (depending on the cancer, perhaps in the single digits), and even drugs that work on these mutations may not provide the desired response rates. There is lots of room to improve. "Functional testing" directly tests cancer drugs on your live cancer cells to see what the drugs do. This is in contrast to, say, a test which genomically profiles a tumor and then uses this information to predict how well drugs might work, based on the underlying mechanistic understanding of the drugs. It’s the difference between theorizing about something and trying it. Is functional testing something you should consider? For more, please see our discussion with Dennis Watson, Vice President of Business Development at Travera; Mark Stevens, Travera’s vice president of clinical development; and Rob Kimmerling, Travera’s chief technical officer. Mark and Rob were in the lab at MIT where Travera’s unique weighing technology was developed. Travera takes your live cancer cells and then challenges them with different FDA-approved drugs and measures how they respond by weighing the cells using an amazingly precise microscopic device: https://lnkd.in/dRuMYQjw

Need a refresher on immune checkpoints that are targets for cancer therapy? There are a lot of targets, and the therapy is often antibody-based. This recently published review covers the topic nicely. Promising novel targets discussed include ICOS, VISTA, TIGIT, CD112R, BTLA, TIM-3, GITR, NKG2A. #immunotherapy #mabs https://lnkd.in/dMSEiXXz

Multitargeting Prodrugs Induce Immunogenic Cell Death: Our latest research unveils a promising cancer treatment that combines three potent drugs to inhibit tumor growth and boost the immune response. Do check out the future of cancer therapy & share your thoughts about it! The Hebrew University of Jerusalem https://lnkd.in/eyMYa5ps #cancerresearch #immunotherapy #oncologyresearch #platinumchemotherapy #dangibsonlab

Neutrophil Extracellular Traps (NETs) are a driver of cancer progression and metastasis and can also limit the effectiveness of current cancer therapies. Take a look at our DNase I #oncology platform here: https://bit.ly/43jxnTE #CARTcells #DNase

Doxil®, the first FDA-approved nano-drug (1995), was a groundbreaking achievement in cancer treatment. It uses innovative technology to deliver medicine directly to tumors. Here's a simplified look at how it works: Targeted Delivery: Doxil® leverages nanoparticles (PEGylated nano-liposomes) coated with a special material to circulate longer in the bloodstream to exploit the enhanced permeability and retention (EPR) effect, improved drug accumulation at the target site and fewer dose-limiting toxicities and avoid healthy tissues. Precise Cargo: These particles carry a powerful anti-cancer drug called doxorubicin. Anti-cancer drug Release: Once near tumors, the particles release the doxorubicin to fight cancer cells. This innovative approach has improved cancer treatment, paving the way for further advancements in nanomedicine. 😊 😊